Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Current Opinion in Rheumatology|December 23, 2021
B cells in systemic lupus erythematosusFranziska Szelinski, Andreia C Lino, Thomas Dörner
RMD Open|July 18, 2020
Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosusThomas Dörner, Franziska Szelinski, Andreia C Lino, et al.
Annals of the Rheumatic Diseases|August 23, 2025
SLE classification criteria item relationships: implications on SLE as a disease entityMartin Aringer, Franziska Szelinski, Thomas Dörner, et al.
Rheumatology (Oxford, England)|May 2, 2020
Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibilityArman Aue, Franziska Szelinski, Sarah Y Weißenberg, et al.
Current Opinion in Rheumatology|December 13, 2018
Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerationsEva Schrezenmeier, Sarah Y Weißenberg, Ana-Luisa Stefanski, et al.
RMD Open|January 27, 2017
SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndromeThomas Rose, Franziska Szelinski, Anna Lisney, et al.
Frontiers in Immunology|October 13, 2025
Soluble checkpoint molecules as predictive biomarker for disease activity and long-term outcome in SLELéa-Sophie Dreveton, Jakob Joachim Spencker, Hector Rincon-Arevalo, et al.
Frontiers in Immunology|February 12, 2019
Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus NephritisMariele Gatto, Annika Wiedemann, Nadja Nomovi, et al.
Frontiers in Immunology|May 6, 2022
B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated PatientsAna-Luisa Stefanski, Hector Rincon-Arevalo, Eva Schrezenmeier, et al.
Pageof 3